Stephen Castellino

List of Publications by Year
in descending order

43 papers	2,484 citations	236925 25 h-index	302126 39 g-index
44 all docs	44 docs citations	44 times ranked	2792 citing authors

#	Article	IF	Citations
1	The emergence of imaging mass spectrometry in drug discovery and development: Making a difference by driving decision making. Journal of Mass Spectrometry, 2021, 56, e4717.	1.6	12
2	Guest editorial for special issue on imaging mass spectrometry. Journal of Mass Spectrometry, 2020, 55, e4507.	1.6	0
3	Special issue on imaging mass spectrometry. Journal of Mass Spectrometry, 2020, 55, ii-ii.	1.6	0
4	Intramuscular and subcutaneous drug depot characterization of a long-acting cabotegravir nanoformulation by MALDI IMS. International Journal of Mass Spectrometry, 2019, 437, 92-98.	1.5	13
5	Quantification and assessment of detection capability in imaging mass spectrometry using a revised mimetic tissue model. Bioanalysis, 2019, 11, 1099-1116.	1.5	39
6	Multicenter Validation Study of Quantitative Imaging Mass Spectrometry. Analytical Chemistry, 2019, 91, 6266-6274.	6.5	51
7	An Investigation into Retigabine (Ezogabine) Associated Dyspigmentation in Rat Eyes by MALDI Imaging Mass Spectrometry. Chemical Research in Toxicology, 2019, 32, 294-303.	3.3	37
8	HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2. Clinical Cancer Research, 2017, 23, 4323-4334.	7.0	64
9	Multimodal imaging approach to examine biodistribution kinetics of Cabotegravir (GSK1265744) long acting parenteral formulation in rat. Journal of Controlled Release, 2017, 268, 102-112.	9.9	25
10	Drug-induced Liver Fibrosis. Toxicologic Pathology, 2016, 44, 112-131.	1.8	20
11	MALDI Imaging MS: Molecular Visualization of Tissues in Drug Discovery and Development. Microscopy and Microanalysis, 2015, 21, 2229-2230.	0.4	1
12	Imaging MS in Toxicology: An Investigation of Juvenile Rat Nephrotoxicity Associated with Dabrafenib Administration. Journal of the American Society for Mass Spectrometry, 2015, 26, 887-898.	2.8	44
13	Assessing drug and metabolite detection in liver tissue by UV-MALDI and IR-MALDESI mass spectrometry imaging coupled to FT-ICR MS. International Journal of Mass Spectrometry, 2015, 377, 448-455.	1.5	50
14	Investigation of Blue Bedding in Cages Housing Treatment-NaÃ¯ve Hamsters. Journal of the American Association for Laboratory Animal Science, 2015, 54, 799-802.	1.2	0
15	Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir. European Journal of Clinical Pharmacology, 2014, 70, 1173-1179.	1.9	31
16	Cardiolipin profiles as a potential biomarker of mitochondrial health in dietâ€induced obese mice subjected to exercise, dietâ€restriction and ephedrine treatment. Journal of Applied Toxicology, 2014, 34, 1122-1129.	2.8	9
17	A Mimetic Tissue Model for the Quantification of Drug Distributions by MALDI Imaging Mass Spectrometry. Analytical Chemistry, 2013, 85, 10099-10106.	6.5	168
18	Central Nervous System Disposition and Metabolism of Fosdevirine (GSK2248761), a Non-Nucleoside Reverse Transcriptase Inhibitor: An LC-MS and Matrix-Assisted Laser Desorption/Ionization Imaging MS Investigation into Central Nervous System Toxicity. Chemical Research in Toxicology, 2013, 26, 241-251.	3.3	67

#	Article	IF	Citations
19	Metabolism, Excretion, and Mass Balance of the HIV-1 Integrase Inhibitor Dolutegravir in Humans. Antimicrobial Agents and Chemotherapy, 2013, 57, 3536-3546.	3.2	119
20	MALDI imaging MS analysis of drug distribution in tissue: the right time!(?). Bioanalysis, 2012, 4, 2549-2551.	1.5	24
21	Human Metabolism of Lapatinib, a Dual Kinase Inhibitor: Implications for Hepatotoxicity. Drug Metabolism and Disposition, 2012, 40, 139-150.	3.3	85
22	Assessment of the Drug Interaction Risk for Remogliflozin Etabonate, a Sodium-Dependent Glucose Cotransporter-2 Inhibitor: Evidence from In Vitro, Human Mass Balance, and Ketoconazole Interaction Studies. Drug Metabolism and Disposition, 2012, 40, 2090-2101.	3.3	33
23	Lapatinib Distribution in HER2 Overexpressing Experimental Brain Metastases of Breast Cancer. Pharmaceutical Research, 2012, 29, 770-781.	3.5	182
24	MALDI imaging mass spectrometry: bridging biology and chemistry in drug development. Bioanalysis, 2011, 3, 2427-2441.	1.5	212
25	The disposition and metabolism of GW695634: A non-nucleoside reverse transcriptase inhibitor (NNRTi) for treatment of HIV/AIDS. Xenobiotica, 2010, 40, 437-445.	1.1	7
26	An Unexpected Synergist Role of P-Glycoprotein and Breast Cancer Resistance Protein on the Central Nervous System Penetration of the Tyrosine Kinase Inhibitor Lapatinib (N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine;) Tj ETQq0	3.3	246
27	The Role of Efflux and Uptake Transporters inN-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, Lapatinib) Disposition and Drug Interactions. Drug Metabolism and Disposition, 2008, 36, 695-701.	3.3	226
28	An Investigation of the Binding Site of Î±2u-Globulin Using Isotopically Labeled Ligands and Inverse Nuclear Magnetic Resonance Techniques1. Chemical Research in Toxicology, 1996, 9, 215-222.	3.3	4
29	Syntheses, Structures, and Reactions of Sulfur and Selenium Insertion Products of 1,1-Di-tert-butylsiliranes. Organometallics, 1994, 13, 3715-3727.	2.3	35
30	Synthesis and Characterization of Two Aromatic Silicon-Containing Dianions:The 2,3,4,5-Tetraphenylsilole Dianion and the 1,1'-Disila-2,2',3,3',4,4',5,5'-Octaphenylfulvalene Dianion. Organometallics, 1994, 13, 3387-3389.	2.3	136
31	Chelation controlled reactions of Et2AlCl and carbomethoxy substituted dioxolanes. Tetrahedron Letters, 1993, 34, 967-970.	1.4	6
32	Diethylaluminum chloride complexes of an N-acyloxazolidinone: NMR investigation. Journal of the American Chemical Society, 1993, 115, 2986-2987.	13.7	82
33	EPSP synthase inhibitor design I. Conformations of enzyme bound shikimate-3-phosphate and 5-enolpyruvoylshikimate-3-phosphate using TRNOE. Bioorganic and Medicinal Chemistry Letters, 1992, 2, 151-154.	2.2	15
34	Solution conformations of two shikimate 3-phosphates: determination by NMR and molecular mechanics calculations. Journal of Organic Chemistry, 1991, 56, 5176-5181.	3.2	13
35	Tin tetrachloride chelation of an N-acyloxazolidinone: an NMR investigation. Journal of Organic Chemistry, 1990, 55, 5197-5200.	3.2	37
36	The mechanism of tin tetrachloride promoted additions of allylstannanes to aldehydes: a response to Denmark, Wilson, and Willson. Journal of the American Chemical Society, 1989, 111, 8136-8141.	13.7	66

#	Article	IF	Citations
37	Direct Evidence for the Absence of Chelation with Î²-Silyloxy Aldehydes and Lewis Acids. Tetrahedron Letters, 1987, 28, 281-284.	1.4	78
38	Dramatic effects of oxygen substituents on 1,3-asymmetric induction in additions of allyltriphenylstannane to .beta.-alkoxy aldehydes: a chemical and spectroscopic investigation. Journal of Organic Chemistry, 1986, 51, 5478-5480.	3.2	64
39	On the origins of stereoselectivity in chelation controlled nucleophilic additions to .beta.-alkoxy aldehydes: solution structures of Lewis acid complexes via NMR spectroscopy. Journal of the American Chemical Society, 1986, 108, 3847-3849.	13.7	103
40	Synthesis of 3-oxo-Î´-lactones via hetero-Diels-Alder reactions. Tetrahedron Letters, 1984, 25, 2307-2310.	1.4	32
41	The total synthesis of (Â±) kawain via a hetero-diels-alder cycloaddition. Tetrahedron Letters, 1984, 25, 4059-4062.	1.4	27
42	A carbon-13 nuclear magnetic resonance study on an organophosphate. Formation and characterization of methamidophos (O,S-dimethyl phosporamidothioate) S-oxide. Journal of Organic Chemistry, 1984, 49, 1696-1699.	3.2	8
43	Revised Preparation of a Mimetic Tissue Model for Quantitative Imaging Mass Spectrometry. Protocol Exchange, 0, , .	0.3	13